
- September 2007
- Volume 24
- Issue 9
Do we need to do a better job of undertaking antithrombotic therapy in the elderly?
The increasing prevalence of atrial fibrillation in the elderly, especially compared with younger age groups, is striking (8% in persons > 80 years compared with 1% in those < 60 years).
The increasing prevalence of atrial fibrillation in the elderly, especially compared with younger age groups, is striking (8% in persons > 80 years compared with 1% in those < 60 years).1 This arrhythmia presents several management problems for physicians that are intensified in the elderly. In general, patients over age 65 have medication compliance issues, and having chronic atrial fibrillation certainly compounds this problem. Affected patients will usually require medication to control the ventricular rate and with few exceptions nearly always require either aspirin or warfarin (or in some cases the newer heparin preparations) to minimize the incidence of thromboembolic events, especially ischemic strokes (which are the most devastating complication of atrial fibrillation).
In their study, Monte et al
What is to account for this under use of antithrombotic therapy in an elderly population, and how can it be corrected? There is no simple answer. What makes this dilemma harder to understand in the population studied is the fact that all treatments and office visits were fully reimbursable and easily accessible under Italy's national health system. Despite this, both doctors and patients bear responsibility for the underutilization. (This situation, by the way, is not unique to Italy.3) Although I understand the concerns of the elderly patient about internal bleeding after falling (this age group is prone to falls, after all), it is up to the physician to reassure patients that antithrombotic therapy should be undertaken in all but a minority of elderly patients with atrial fibrillation because it can help prevent crippling strokes. This is a public health education issue of the highest magnitude and should be treated as such.
Articles in this issue
over 17 years ago
Beginning antithrombotic therapy in an 84-year-old womanalmost 18 years ago
Achieving LDL cholesterol goals in elderly patients with ACSalmost 18 years ago
Never too old for statinsalmost 18 years ago
Predicting survival in elderly patients with heart failurealmost 18 years ago
Predicting heart failure survival: Value of a mortality risk scorealmost 18 years ago
A roundup of breaking cardiac newsalmost 18 years ago
Statins and cancer in the elderlyalmost 18 years ago
Low cholesterol, statins, and cancer risk: Déjà vu all over again


























































